Related references
Note: Only part of the references are listed.Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
Anthony Lucci et al.
CLINICAL CANCER RESEARCH (2020)
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
Muhammad A. Khattak et al.
ONCOLOGIST (2020)
Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process-A systematic review
Antonino Guerrisi et al.
CANCER MEDICINE (2020)
Lactate dehydrogenase: a marker of diminished antitumor immunity
Sandra Van Wilpe et al.
ONCOIMMUNOLOGY (2020)
Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy
Matteo Allegretti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy
Xiaodong Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H. Lee et al.
NATURE COMMUNICATIONS (2020)
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
Haris Babacic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma
Magali Boyer et al.
CANCERS (2020)
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
Carol M. Amato et al.
CANCERS (2020)
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Gabriela Marsavela et al.
CLINICAL CANCER RESEARCH (2020)
Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma
Junjie Jiang et al.
CANCER MEDICINE (2020)
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Italia Falcone et al.
CANCERS (2020)
A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery
Jessica Gasparello et al.
CANCERS (2020)
Radiomics: an overview in lung cancer management-a narrative review
Bojiang Chen et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy
Samantha M. Morrissey et al.
TRENDS IN CANCER (2020)
Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis
Marco Tucci et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
S. Trebeschi et al.
ANNALS OF ONCOLOGY (2019)
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Neda Yaghoubi et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Exosomes: biogenesis, biologic function and clinical potential
Yuan Zhang et al.
CELL AND BIOSCIENCE (2019)
PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
Chiara Bazzichetto et al.
CANCERS (2019)
Life and death of circulating cell-free DNA
Anatoli Kustanovich et al.
CANCER BIOLOGY & THERAPY (2019)
Detection of circulating tumor cells in colorectal cancer patients using the GILUPI CellCollector: results from a prospective, single-center study
Levent Dizdar et al.
MOLECULAR ONCOLOGY (2019)
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study
Andrea Forschner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells
Laure Cayrefourcq et al.
CELLS (2019)
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence
Michal Harel et al.
CELL (2019)
The Need for Multi-Omics Biomarker Signatures in Precision Medicine
Michael Olivier et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma
Hanna Saadani et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
The role of exosomal PD-L1 in tumor progression and immunotherapy
Feiting Xie et al.
MOLECULAR CANCER (2019)
Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming
Edina Gyukity-Sebestyen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y. Lim et al.
CLINICAL CANCER RESEARCH (2019)
Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab
Carole Durot et al.
EUROPEAN RADIOLOGY (2019)
Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy
Amadeus Schraag et al.
EUROPEAN JOURNAL OF RADIOLOGY (2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
Maartje G. Schouwenburg et al.
CANCERS (2019)
Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy
Laura Keller et al.
ACTA DERMATO-VENEREOLOGICA (2019)
Clinical multi-omics strategies for the effective cancer management
Byong Chul Yoo et al.
JOURNAL OF PROTEOMICS (2018)
Oridonin inhibits migration, invasion, adhesion and TGF-β1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/Akt/GSK-3β signaling pathway
Chun-Yu Li et al.
ONCOLOGY LETTERS (2018)
PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma
Ying-Ming Chiu et al.
ANTICANCER RESEARCH (2018)
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Nikolaus B. Wagner et al.
BRITISH JOURNAL OF CANCER (2018)
Apoptosis: A Target for Anticancer Therapy
Claire M. Pfeffer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Cutaneous melanoma: From pathogenesis to therapy (Review)
Giulia C. Leonardi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Emergencies in the Treatment of Wandering Spleen
Osher Cohen et al.
ISRAEL MEDICAL ASSOCIATION JOURNAL (2018)
Immunotherapy of melanoma
Iwona Lugowska et al.
Wspolczesna Onkologia-Contemporary Oncology (2018)
Biomarkers for Clinical Benefit of immune Checkpoint inhibitor Treatment-A Review From the Melanoma Perspective and Beyond
Kristina Buder-Bakhaya et al.
FRONTIERS IN IMMUNOLOGY (2018)
Biomarkers for immune Checkpoint inhibitors in Melanoma
Shigehisa Kitano et al.
FRONTIERS IN ONCOLOGY (2018)
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander et al.
NATURE MEDICINE (2018)
MEK inhibitors for the treatment of NRAS mutant melanoma
Saro Sarkisian et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Mal Irvine et al.
ONCOGENESIS (2018)
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
Xin Hong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
Raffaele Palmirotta et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Radiomics: the bridge between medical imaging and personalized medicine
Philippe Lambin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells
G-A Franzetti et al.
ONCOGENE (2017)
Transcriptomics technologies
Rohan Lowe et al.
PLOS COMPUTATIONAL BIOLOGY (2017)
Circulating Tumor DNA as Biomarkers for Cancer Detection
Xiao Han et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
J. H. Lee et al.
ANNALS OF ONCOLOGY (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Problems, challenges and promises: perspectives on precision medicine
David J. Duffy
BRIEFINGS IN BIOINFORMATICS (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
Liqiang Xi et al.
CLINICAL CANCER RESEARCH (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation
Andrelou F. Vallarelli et al.
ONCOTARGET (2016)
Technical challenges in the isolation and analysis of circulating tumor cells
Emma E. van der Toom et al.
ONCOTARGET (2016)
Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients
Andra Kuskel et al.
SCIENTIFIC REPORTS (2016)
Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study
Christina L. Roland et al.
MELANOMA RESEARCH (2015)
The Genetic Evolution of Melanoma from Precursor Lesions
A. Hunter Shain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities
M. Vallieres et al.
PHYSICS IN MEDICINE AND BIOLOGY (2015)
Exosomes in bodily fluids are a highly stable resource of disease biomarkers
Stephanie Boukouris et al.
PROTEOMICS CLINICAL APPLICATIONS (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Katarzyna Tomczak et al.
Wspolczesna Onkologia-Contemporary Oncology (2015)
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Sander Kelderman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan et al.
CANCER RESEARCH (2014)
Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin
Todd D. Prickett et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Hugo J. W. L. Aerts et al.
NATURE COMMUNICATIONS (2014)
OPINION Challenges in circulating tumour cell research
Catherine Alix-Panabieres et al.
NATURE REVIEWS CANCER (2014)
Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
Simone M. Goldinger et al.
EJC SUPPLEMENTS (2013)
Analysis of Circulating Tumor Cells in Breast Cancer
Zeynep Eroglu et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
S. Kruijff et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Melanoma: from mutations to medicine
Hensin Tsao et al.
GENES & DEVELOPMENT (2012)
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing
Mitchell S. Stark et al.
NATURE GENETICS (2012)
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Sergey I. Nikolaev et al.
NATURE GENETICS (2012)
Metabolomics: the apogee of the omics trilogy
Gary J. Patti et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
W. Deng et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model
Catalina Trejo-Becerril et al.
PLOS ONE (2012)
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
F. Farace et al.
BRITISH JOURNAL OF CANCER (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell et al.
ONCOTARGET (2011)
Circulating Tumor Cells and Melanoma Progression
Xiaowei Xu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure
Despina Handolias et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
Sanjiv S. Agarwala et al.
EUROPEAN JOURNAL OF CANCER (2009)
Advanced Segmentation Techniques for Lung Nodules, Liver Metastases, and Enlarged Lymph Nodes in CT Scans
Jan Hendrik Moltz et al.
IEEE JOURNAL OF SELECTED TOPICS IN SIGNAL PROCESSING (2009)
Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro
Malihe Eskandarpour et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
A novel AKT3 mutation in melanoma tumours and cell lines
M. A. Davies et al.
BRITISH JOURNAL OF CANCER (2008)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Cancer genes and the pathways they control
B Vogelstein et al.
NATURE MEDICINE (2004)
Frequent EpCam protein expression in human carcinomas
PT Went et al.
HUMAN PATHOLOGY (2004)
S100 serum level: a tumour marker for metastatic melanoma
U Bottoni et al.
MELANOMA RESEARCH (2003)
Apoptosis and melanoma: molecular mechanisms
MR Hussein et al.
JOURNAL OF PATHOLOGY (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
About the possible origin and mechanism of circulating DNA - Apoptosis and active DNA release
M Stroun et al.
CLINICA CHIMICA ACTA (2001)
Horizontal transfer of oncogenes by uptake of apoptotic bodies
A Bergsmedh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
